[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ventriculitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ventriculitis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100565970","clearance-of-intracranial-blood-products-by-continuous-irrigation-with-the-irraflow-system-100565970",false,"NCT06649097","Clearance of Intracranial Blood Products by Continuous Irrigation With the IRRAflow System","CRYSTAL","Inclusion criteria:\n\n* Age \\>=18 years of age\n* Intracranial hemorrhage documented on head CT or MRI scan.\n* Indication for active fluid exchange evaluated by treating physician.\n* Signed informed consent obtained by patient or Legal Authorized Representative\n* Scheduled enrollment and treatment within 72 hours of last known well (LKW)\n\nExclusion criteria:\n\n* GCS ≤ 5\n* Pregnancy\n* Fixed and dilated pupil\n* Life-threatening medical condition","ALL","18 Years",{"count":19,"type":20},250,"ESTIMATED","6 Months","OBSERVATIONAL","The study is a multi-center prospective cohort, controlled, phase 4 post-market registry evaluating the efficacy and radiographic outcomes associated with the use of the IRRAflow® Active Fluid Exchange System compared to standard of care external ventricular drains.",[25,26,27],"Intracranial Hemorrhage","Ventriculitis","Intracranial Abscess","RECRUITING","2025-10-24",{"date":31,"type":32},"2025-10-28","ACTUAL",{"date":34,"type":32},"2025-09-25",{"date":36,"type":20},"2031-07",{"name":38,"class":39},"Christopher P Kellner","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":40},"100489191","affect-study-for-patients-with-intraventricular-hemorrhage-subarachnoid-hemorrhage-subdural-hematoma-and-ventriculitis-100489191","NCT05649904","AFFECT Study for Patients With Intraventricular Hemorrhage, Subarachnoid Hemorrhage, Subdural Hematoma, and Ventriculitis","Use of Active Fluid Exchange to Therapeutically Treat Intracranial Bleeding and Infection","AFFECT","Inclusion Criteria:\n\n1. Age ≥18 years of age\n2. Need of drainage for one of the following underlying conditions: Intraventricular hemorrhage, intracranial hemorrhage, subarachnoid hemorrhage, chronic subdural hematoma and ventriculitis\n3. Indication for active treatment evaluated by treating physician for underlying conditions; Intraventricular hemorrhage, subarachnoid hemorrhage, chronic subdural hematoma and ventriculitis\n4. Signed informed consent obtained by subject or Legally Authorized Representative\n\nExclusion Criteria:\n\n1. Subject has fixed and dilated pupils\n2. Pregnant women\n3. Presence of Moyamoya\n4. History or presence of clotting disorder.\n5. Platelet count less than 100,000, INR greater than 1.4",{"count":50,"type":20},240,"INTERVENTIONAL",[53],"NA","The goal of this clinical trial is to evaluate efficacy and safety of evacuation of cerebrospinal fluid, blood, and harmful bacteria from the intraventricular, subdural and subarachnoid spaces by Active Controlled Irrigation and Drainage (IRRAflow) compared to Passive External Ventricular Drainage (EVD).\n\nSubjects with intraventricular hemorrhage, subarachnoid hemorrhage, subdural bleeding, and ventriculitis will be randomized to receive the IRRAflow device or EVD device and followed for one month post-procedure to compare outcomes between the subject groups.",[56,57,58,26],"Intraventricular Hemorrhage","Subarachnoid Hemorrhage","Subdural Hematoma","2025-03-26",{"date":61,"type":32},"2025-04-01",{"date":63,"type":32},"2023-02-07",{"date":65,"type":20},"2026-01",{"name":67,"class":39},"Ohio State University"]